Cargando…

Prognostic value of monitoring tumour markers CA 15-3 and CEA during fulvestrant treatment

BACKGROUND: At many centres tumour markers are used to detect disease recurrence and to monitor response to therapy in patients with advanced disease, although the real value of serial observation of marker levels remains disputed. In this study, we evaluated the prognostic value of tumour markers f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bartsch, Rupert, Wenzel, Catharina, Pluschnig, Ursula, Hussian, Dagmar, Sevelda, Ursula, Altorjai, Gabriela, Locker, Gottfried J, Mader, Robert, Zielinski, Christoph C, Steger, Guenther G
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2006
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1435763/ https://www.ncbi.nlm.nih.gov/pubmed/16563172 http://dx.doi.org/10.1186/1471-2407-6-81

Ejemplares similares

Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: An observational study
por: Bartsch, Rupert, et al.
Publicado: (2006)

Expression of thymidine phosphorylase in peripheral blood cells of breast cancer patients is not increased by paclitaxel
por: Bartsch, Rupert, et al.
Publicado: (2007)

Indocyanine Green Video Angiography Predicts Outcome of Extravasation Injuries
por: Haslik, Werner, et al.
Publicado: (2014)

Extravasation emergencies: state-of-the-art management and progress in clinical research
por: Pluschnig, Ursula, et al.
Publicado: (2016)

Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer
por: Bartsch, Rupert, et al.
Publicado: (2009)

Trastuzumab in the management of early and advanced stage breast cancer
por: Bartsch, Rupert, et al.
Publicado: (2007)

Single-agent pegylated liposomal doxorubicin (PLD) in the treatment of metastatic breast cancer: results of an Austrian observational trial
por: Fiegl, Michael, et al.
Publicado: (2011)

Tissue distribution of epirubicin after severe extravasation in humans
por: Nedomansky, Jakob, et al.
Publicado: (2021)

Tumour marker antigen CA125 in pancreatic cancer: a comparison with CA19-9 and CEA.
por: Haglund, C.
Publicado: (1986)

Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases
por: Nicolini, Andrea, et al.
Publicado: (2006)

CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA.
por: Haglund, C., et al.
Publicado: (1994)

Relationship of serum CEA levels to tumour size and CEA content in nude mice bearing colonic-tumour xenografts.
por: Lewis, J. C., et al.
Publicado: (1981)

The use of tumour markers CEA, CA-195 and CA-242 in evaluating the response to chemotherapy in patients with advanced colorectal cancer.
por: Ward, U., et al.
Publicado: (1993)

The site of binding of anti-CEA antibodies to tumour CEA in vivo: an immunocytochemical and autoradiographic approach.
por: Moshakis, V., et al.
Publicado: (1982)

Clinical utility of tumour marker velocity of cancer antigen 15–3 (CA 15–3) and carcinoembryonic antigen (CEA) in breast cancer surveillance
por: Hing, J.X., et al.
Publicado: (2020)

Comparison of a new tumour marker CA 242 with CA 19-9, CA 50 and carcinoembryonic antigen (CEA) in digestive tract diseases.
por: Kuusela, P., et al.
Publicado: (1991)

Updated Austrian treatment algorithm in HER2+ metastatic breast cancer
por: Bartsch, Rupert, et al.
Publicado: (2022)

Tumour-associated trypsin inhibitor (TATI) in human ovarian cyst fluid. Comparison with CA 125 and CEA.
por: Halila, H., et al.
Publicado: (1987)

Serum CEA and CA 15-3 as prognostic factors in primary breast cancer
por: Ebeling, F G, et al.
Publicado: (2002)

Retrospective Evaluation of Fulvestrant Efficacy and Clinical Results in Patients Using Fulvestrant
por: Kut, Engin, et al.
Publicado: (2023)

Fulvestrant: pharmacokinetics and pharmacology
por: Robertson, J F R, et al.
Publicado: (2004)

The effect of serum CEA on the distribution and clearance of anti-CEA antibody in a pancreatic tumour xenograft model.
por: Pedley, R. B., et al.
Publicado: (1989)

The prognostic role of variations in tumour markers (CEA, CA15.3) in patients with metastatic breast cancer treated with CDK4/6 inhibitors
por: Sottotetti, Federico, et al.
Publicado: (2022)

Primary Cutaneous Mucinous Carcinoma Monitoring: A Role for CA15.3 and CEA?
por: Ginguay, Antonin, et al.
Publicado: (2022)

Diagnostic impact of CEA and CA 15-3 on chemotherapy monitoring of breast cancer patients
por: Hasan, Diya
Publicado: (2022)

CEA but not CA19-9 is an independent prognostic factor in patients undergoing resection of cholangiocarcinoma
por: Loosen, Sven H., et al.
Publicado: (2017)

Immunological comparison of carcinoembryonic antigen (CEA) extracted from tumours of various organs: their use in radioimmunological CEA determinations.
por: Lamerz, R., et al.
Publicado: (1983)

Nipple Discharge of CA15-3, CA125, CEA and TSGF as a New Biomarker Panel for Breast Cancer
por: Wang, Gangping, et al.
Publicado: (2014)

Diagnostic Utility of Combined CEA, CA15-3 and CA125 Biomarkers and Cytomorphology in Suspicious and Malignant Serosal Fluid
por: Rahemi, Zahra, et al.
Publicado: (2021)

Economic Evaluation for Palbociclib Plus Fulvestrant vs Ribociclib Plus Fulvestrant and Abemaciclib Plus Fulvestrant in Endocrine-Resistant Advanced or Metastatic Breast Cancer in Italy
por: Colombo, Giorgio Lorenzo, et al.
Publicado: (2023)

Association of Preoperative Serum Levels of CEA and CA15-3 with Molecular Subtypes of Breast Cancer
por: Zhao, Wenjing, et al.
Publicado: (2021)

Preoperative serum levels of CEA and CA 242 in colorectal cancer.
por: Carpelan-Holmström, M., et al.
Publicado: (1995)

The Clinical Significance of CEA, CA19–9, and CA125 in Management of Appendiceal Adenocarcinoma
por: Yousef, Abdelrahman, et al.
Publicado: (2023)

Combined Evaluation of AFP, CA15-3, CA125, CA19-9, and CEA Tumor Markers in Patients with Hepatitis B and C
por: ASSMAR, Mehdi, et al.
Publicado: (2016)

Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases
por: Bartsch, R, et al.
Publicado: (2012)

Tumour lysis as a factor affecting blood levels of CEA.
por: Quayle, J. B.
Publicado: (1982)

Comparison of CA-50, a new tumour marker, with carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP) in patients with gastrointestinal diseases.
por: Kuusela, P., et al.
Publicado: (1987)

Receiver operating characteristic (ROC) curve analysis of the tumour markers CEA, CA 50 and CA 242 in pancreatic cancer; results from a prospective study.
por: Pasanen, P. A., et al.
Publicado: (1993)

Immunochemical studies of carcinoembryonic antigen (CEA) variants.
por: Ichiki, A. T., et al.
Publicado: (1976)

Menstrual Cycle Dependent Variability for Serum Tumor Markers CEA, AFP, CA 19-9, CA 125 and CA 15-3 in Healthy Women
por: Erbağci, Ayşe Binnur, et al.
Publicado: (1999)

Cannot write session to /tmp/vufind_sessions/sess_e3b2l7mo9dg5t4htnpngcgfbim